Business Description
Fulcrum Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US3596161097
Total Employee Number:
55Description
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 56.81 | |||||
Equity-to-Asset | 0.96 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | -0.07 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 18.6 | |||||
3-Year EPS without NRI Growth Rate | 21.4 | |||||
3-Year FCF Growth Rate | 24.3 | |||||
3-Year Book Growth Rate | 11.1 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 14.19 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 28.44 | |||||
9-Day RSI | 34.66 | |||||
14-Day RSI | 34.64 | |||||
3-1 Month Momentum % | -53.51 | |||||
6-1 Month Momentum % | -64.37 | |||||
12-1 Month Momentum % | -56.18 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 34.33 | |||||
Quick Ratio | 34.33 | |||||
Cash Ratio | 33.79 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -8.5 | |||||
Shareholder Yield % | 0.9 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -28.75 | |||||
ROA % | -27.2 | |||||
ROIC % | -738.26 | |||||
3-Year ROIIC % | -241.29 | |||||
ROC (Joel Greenblatt) % | -1128.92 | |||||
ROCE % | -32.11 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 0.7 | |||||
Price-to-Tangible-Book | 0.7 | |||||
EV-to-EBIT | 1.09 | |||||
EV-to-EBITDA | 1.11 | |||||
EV-to-Forward-Revenue | 3.67 | |||||
EV-to-FCF | 1.48 | |||||
Price-to-GF-Value | 0.11 | |||||
| Price-to-Net-Current-Asset-Value | 0.72 | |||||
| Price-to-Net-Cash | 0.73 | |||||
Earnings Yield (Greenblatt) % | 91.74 | |||||
FCF Yield % | -27.26 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:FULC
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Fulcrum Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.15 | ||
| Beta | 2.7027 | ||
| 3-Year Sharpe Ratio | 0.47 | ||
| 3-Year Sortino Ratio | 0.83 | ||
| Volatility % | 75.37 | ||
| 14-Day RSI | 34.64 | ||
| 14-Day ATR ($) | 0.282321 | ||
| 20-Day SMA ($) | 3.6565 | ||
| 12-1 Month Momentum % | -56.18 | ||
| 52-Week Range ($) | 2.83 - 15.7399 | ||
| Shares Outstanding (Mil) | 66.63 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Fulcrum Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Fulcrum Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-10-29 08:00 | In 111 days | ||
| Third quarter earnings results for 2026 | 2026-10-29 | In 110 days | ||
| Second quarter earnings results for 2026 | 2026-07-29 06:48 | In 19 days | ||
| General meeting for 2026 | 2026-06-26 09:00 | 3.61 (-4.50%) | ||
| First quarter earnings conference call for 2026 | 2026-04-27 08:00 | 7.84 (-2.37%) | ||
| First quarter earnings results for 2026 | 2026-04-27 | 7.84 (-2.37%) | ||
| Leerink Partners Global Healthcare Conference | 2026-03-10 13:00 | 7.94 (+1.53%) | ||
| Annual report for 2025 | 2026-02-24 | 10.89 (-1.71%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-24 | 10.89 (-1.71%) | ||
| 44th Annual J.P. Morgan Healthcare Conference | 2026-01-14 10:30 | 10.25 (+8.81%) |
Show
Entries
Fulcrum Therapeutics Inc Frequently Asked Questions
What is Fulcrum Therapeutics Inc(FULC)'s stock price today?
The current price of FULC is $3.49. The 52 week high of FULC is $15.74 and 52 week low is $2.83.
When is next earnings date of Fulcrum Therapeutics Inc(FULC)?
The next earnings date of Fulcrum Therapeutics Inc(FULC) is 2026-07-29 Est..
Does Fulcrum Therapeutics Inc(FULC) pay dividends? If so, how much?
Fulcrum Therapeutics Inc(FULC) does not pay dividend.
Guru Commentaries on NAS:FULC
No articles.
Press Release
Articles on Fulcrum Therapeutics Inc
Insider Sell Alert: Alan Ezekowitz Sells 18,000 Shares of Fulcrum Therapeutics Inc (FULC)
Jun 30, 2026
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers